We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.60
Bid: 3.60
Ask: 4.08
Change: 0.00 (0.00%)
Spread: 0.48 (13.333%)
Open: 3.60
High: 3.60
Low: 3.60
Prev. Close: 3.60
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Argentina approves Harpin as a seed treatment

1 Sep 2021 07:00

RNS Number : 1012K
Plant Health Care PLC
01 September 2021
 

RNS

1 September 2021

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

Argentina approves Harpin ab for use as a seed treatment in Corn and Soybeans

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce the registration approval of Harpin ab for use as a seed treatment in Argentina.

 

The regulatory process in Argentina for agricultural products involves detailed review and approval by Senasa, the Country's National Food Safety and Quality Service, which classified Harpin ab as a biostimulant organic-chemical fertilizer. This confirms the Argentinian government's commitment to promoting cost effective, sustainable and safe products.

 

Highlights

· Corn and soybeans are the first crops to receive regulatory approval for Harpin ab in Argentina.

· Argentina has 24 million hectares (60 million acres) of corn and soybeans planted in the current season. Growers spent more than $100m on soybean seed treatments in Argentina in the most recent season. The size of the biological market in soybeans is growing rapidly and was about $75m in 2021.

· The Company is currently working with multiple organizations that are evaluating Harpin ab and will select in-country distribution partners in due course.

 

Harpin ab works by triggering the plant's own self defense systems, leading to a robust physiological response, in a manner similar to vaccinations in humans. The plant responds with improved crop quality, nutrient use efficiency, tolerance to abiotic stress and ultimately, increased yield. Being a biological product, Harpin αβ has a very favorable human and environmental safety profile.

 

Chris Richards, CEO of Plant Health Care, said: ‟Harpin ab registration in Argentina is key to the further expansion of Harpin ab use into large row crop markets."

 

 

For further information, please contact:

 

Plant Health Care plc- Tel: +1 919 926 1600

Chris Richards, CEO

 

Arden Partners plc - Nomad & Joint Broker Tel: +44 (0) 20 7614 5900

John Llewellyn-Lloyd / Antonio Bossi

 

Cenkos Securities plc - Joint Broker Tel: +44 (0) 20 7391 8900

Neil McDonald / Peter Lynch

 

Vox Markets - Digital investor relations Tel: +44 (0) 7866 384707

Paul Cornelius / Kat Perez

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile. Find out more at Vox Markets and the company website: www.planthealthcare.com

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSDLFDSEFSELA
Date   Source Headline
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.